MRNA US S&P 500Russell 1000 Konferencja wynikowa
Moderna
Wyniki II kw. 2026 vs I kw. 2026 · poprzedni kwartał · opublikowano 31 lip 2026 i 1 maj 2026
Net loss narrowed on the previous quarter, guidance cut. Management sounded about as positive as a typical company call, in its script and in answers to analysts.
1 · Liczby
Strata mniejsza
Zysk netto vs I kw. 2026
Prognoza obniżona
Zysk netto -782,0 mln vs -1,34 mld
Przychody −62,7%
Zysk netto -782,0 mln vs -825.0M in II kw. 2025 and -1.34B last quarter.
2 · Jak mówił zarząd
Typowy
Less upbeat than 64% of company calls
Answers to analysts: restrained, in line with the script.
Similar to last call.
3 · Co się wyróżniło
Liczba
Moderna ended the quarter with $6.9 billion in cash and investments, maintaining a strong balance sheet while continuing to invest in its pipeline.
Między wierszami
-
Główny temat
Moderna has been able to enroll the trial, which I think was your question, the cohorts, but the epidemiology of the primary endpoint cases…
Cytat ze źródła
“We have been able to enroll the trial, which I think was your question, the cohorts, but the epidemiology of the primary endpoint cases... But suffice to say, we have -- we are going forward with another season this year. As we had previously discussed, some of that in the first season for that trial was the result of a unique outbreak of a different set of strains of norovirus that were not contributing to that primary endpoint.”
-
Prognoza ↓
Looking at the second half of the year, on the commercial and financial side, Moderna remains on track for up to 10% revenue growth this year and also remain committed to improving its operational efficiency...
-
Prognoza
International revenue for the full year, and Moderna expects third quarter revenue will represent approximately 55% of its second half revenue.
-
Słabnie
Phase III data for norovirus
Cytat ze źródła
“We're also waiting for a Phase III data for norovirus, subject to case approvals, and of our PA programs, which should read out this year. From a pipeline perspective, oncology remains a key focus with upcoming data for Intismeran and mRNA-4359. The team remains focused on disciplined execution across these priorities.”
Wycena
Odwrócony DCF. Wolne przepływy pieniężne z ostatniego pełnego roku obrotowego, powiększane przez 10 lat, zdyskontowane, plus wartość rezydualna. „Wzrost implikowany” to tempo, które zakłada obecna cena.
Wycena niedostępna: negative FCF — no anchor for the model.
Ton
Jak optymistyczny był język w porównaniu z innymi spółkamiiTon to liczba pozytywnych słów finansowych minus liczba negatywnych, skorygowana o długość tekstu. Zarządy zwykle mówią pozytywnie, więc etykiety porównują każdą konferencję z ostatnimi konferencjami wszystkich spółek: „typowy” to środkowa trzecia, „bardzo optymistyczny” to najlepsze 10%, „ostrożny” to najsłabsze 10%.. Kropka: II kw. 2026. Pierścień: I kw. 2026.
Script and answers carried a similar tone, so the script's message held up under questioning.
Zdania, które wpłynęły na ton
“Ester joined us with more than 30 years of commercial leadership experience and an outstanding track record of leading high-performing organization across the health care industry.”
“Slide 13 outlines our multiyear revenue growth strategy, anchored in geographic expansion and portfolio expansion from the continued advancement of our product pipeline.”
“Looking at the second half of the year, on the commercial and financial side, we remain on track for up to 10% revenue growth this year and also remain committed...”
Liczby
USD · SEC EDGAR XBRL (10-Q, period end 2026-06-30)
| Pozycja | II kw. 2026period end 2026-06-30 | I kw. 2026period end 2026-03-31 | Zmiana | II kw. 2025 | r/r |
|---|---|---|---|---|---|
| Przychody | 145,0 mln | 389,0 mln | −62,7% | 142,0 mln | +2,1% |
| Zysk brutto ze sprzedaży | 52,0 mln | — | 23,0 mln | +126,1% | |
| Zysk operacyjny | -815,0 mln | -1,39 mld | Strata mniejsza | -907,0 mln | Strata mniejsza |
| Zysk netto | -782,0 mln | -1,34 mld | Strata mniejsza | -825,0 mln | Strata mniejsza |
| Zysk na akcję | -1,97 | -3,40 | Strata mniejsza | -2,13 | Strata mniejsza |
| C/Z | — | — | — | — | — |
Tematy
Najczęściej omawiane teraz
- For Moderna's norovirus vaccine, mRNA-1403, the Phase III study did not meet the statistical criteria for early success at its...
- Nowe Moderna's Phase III development program also includes studies in adjuvant non-small cell lung cancer, including a Phase III study in...
- Nowe In some cases, you need recommending bodies sort of analogous to CDC recommending body recommendations before you engage in that...
- Nowe On the question of combo in Europe and negotiations, so with approval, Moderna can start the pricing negotiations with many...
- Cost of sales for the quarter was $93 million, a 22% decrease compared to the prior year, primarily driven by...
Zniknęło od I kw. 2026
- Zniknęło Moderna will continue to invest in AI with a number of cross enterprise projects to reinvent work with AI.
- Słabnie Moderna's strong revenue performance year-to-date puts us on a solid path to achieve its full year revenue growth target of...
- Słabnie Moderna definitely have reserved alpha for both of those for what it thinks would still be commercially important products.
Najnowsze komunikaty
Oficjalne raporty spółki, od najnowszych.
- Director or officer change; Regulation FD disclosure · SEC 8-K
- Material agreement; New financial obligation; Unregistered share sale; Other events · SEC 8-K
- Results of operations · SEC 8-K
- Director or officer change; Regulation FD disclosure · SEC 8-K
- Articles or bylaws amended; Shareholder vote results · SEC 8-K
- Results of operations · SEC 8-K
- Material agreement · SEC 8-K
- Results of operations · SEC 8-K